Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form and HIPAA document~* Willing and able to comply with all study procedures~* Be at least 18 years of age~* Patient-reported history of dry eye in both eyes~* Demonstrate a positive response when exposed to the Controlled Adverse Environment model~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~Exclusion Criteria:~* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy~* Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the study period~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.~* Use of any topical ophthalmic preparations (including tear substitutes) 72 hrs prior to screening assessments and through the entire study period~* Any significant illness that could interfere with study parameters~* History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.~* Known history of alcohol and/or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Ophthalmic Solution
- 0.1% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast
- 1.0% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast
- 5.0% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast

Based on this trial design, predict the completion outcome and termination type (if applicable).